Loading organizations...
§ Private Profile · Cardiff, United Kingdom
AI biotechnology company developing an AI platform for antibody discovery, targeting challenging proteins like GPCRs and ion channels.
Based in Cardiff, Wales, with additional teams in Boston and Prague, Antiverse develops an artificial intelligence platform for antibody discovery that targets challenging proteins like G-protein coupled receptors and ion channels to accelerate drug development. The biotechnology company combines structural biology, medicine, and machine learning to identify functional antibodies in as little as six months for its pharmaceutical partners. Operating with a team of 19 employees, the enterprise has raised over $20 million in total funding, which includes a recent $9.3 million Series A round to expand its laboratory facilities. Antiverse is backed by venture capital firms such as Soulmates Ventures and InnoSpark Ventures, and it provides specialized antibody design services to organizations including Nxera Pharma and the Cystic Fibrosis Foundation. The biotechnology firm was originally founded in 2017 by Murat Tunaboylu and Ben Holland.
Antiverse has raised $20.3M across 4 funding rounds.
Antiverse has raised $20.3M in total across 4 funding rounds.
Antiverse has raised $20.3M across 4 funding rounds. Most recently, it raised $9.3M Series A in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 3, 2026 | $9.3M Series A | Michal Sikyta | Rhian Elston, Domino Ventures, I&I Biotech Fund, Lynda Stoelker, Kadmos Capital | Announced |
| Oct 1, 2024 | $5M Seed | Jaromir Zahradka, John Gebeily | G20 Ventures, Innospark Ventures, Angelhub, Tensor Ventures, Uki2s | Announced |
| Mar 2, 2023 | $3M Venture Round | — | ED Parkinson, Angelhub, Deep Science Ventures, Development Bank OF Wales, Matt Fates, Kadmos Capital, Tensor Ventures, Tomorrow Scale | Announced |
| Feb 1, 2023 | $3M Seed | — | G20 Ventures, Innospark Ventures | Announced |
Antiverse has raised $20.3M in total across 4 funding rounds.
Antiverse's investors include Michal Sikyta, Rhian Elston, DOMiNO Ventures, i&i Biotech Fund, Lynda Stoelker, Kadmos Capital, Jaromir Zahradka, John Gebeily, G20 Ventures, Innospark Ventures, AngelHub, Tensor Ventures.
Antiverse is an AI-driven techbio company specializing in computational antibody design for challenging drug targets like G-protein-coupled receptors (GPCRs) and ion channels.[1][2][3] It builds a platform combining machine learning, structural biology, and advanced cell line engineering to generate target-specific antibody libraries, perform deep sequencing analysis, multiparameter clustering, and identify lead candidates for therapeutics and diagnostics, serving pharmaceutical companies and biotech teams tackling complex diseases such as cancer, heart, and lung conditions.[1][2][3][4] The company accelerates drug discovery by delivering functional binders in just 6 months via in silico approaches, has raised £9.6M total funding (including a £3.5M seed led by i&i Biotech Fund), employs 11-50 people, and collaborates with three top global pharma firms while building an internal pipeline.[2][3][5]
Founded in 2017 in Cardiff, UK, Antiverse emerged from the intersection of structural biology, machine learning, and medicine to address gaps in antibody discovery for hard-to-drug targets.[1][2] Co-founders brought expertise from these fields, with the team passionate about engineering breakthroughs in drug development to impact patients globally; one key figure is a former Managing Director at AbbVie Ventures with over 30 years in R&D, business development, and venture capital.[2][3] Early traction included participation in Cambridge Judge Business School's Accelerate Plus program (Cohort 15), securing £5.3M in funds by that point, and partnerships with pharma, leading to a £3.5M seed extension in recent years to expand the team and programs.[2][5]
Antiverse rides the explosive growth in AI-augmented drug discovery, where machine learning slashes development timelines and costs for biologics amid a surge in demand for precision therapies against "undruggable" targets like GPCRs, which represent 30-40% of approved drugs but remain challenging for antibodies.[1][3] Timing aligns with post-2020 AI biotech boom, fueled by advances in protein structure prediction (e.g., AlphaFold) and generative models, enabling scalable in silico screening over wet-lab dependency.[2][4] Market forces favoring Antiverse include big pharma's push for external innovation—evident in its partnerships—and a £9.6M funding warchest amid UK biotech's rise, positioning it to influence the ecosystem by democratizing access to rare antibodies for diagnostics and treatments in oncology and cardiovascular diseases.[3][4][5]
Antiverse is primed to scale its platform through deeper pharma integrations and internal pipeline advancement, potentially yielding first clinical candidates in 2-3 years as AI models mature on proprietary data.[3] Trends like multimodal AI (integrating sequencing, structures, and assays) and expanded GPCR/ion channel focus will propel growth, especially with regulatory tailwinds for AI-derived biologics. Its influence may evolve from service provider to full-fledged therapeutics player, amplifying impact in a market projected to hit billions for AI drug design—echoing its mission to revolutionize detection and treatment of complex diseases.[2][4]